Estimating risk from underpowered, but statistically significant, studies: Was APPROVe on TARGET?

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 6, 2011, Pages 637-641

  La Caze, A ^a   Duffull, S ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

bias; clinical trials; power; rofecoxib

Indexed keywords

MEDICAL RESEARCH; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SAMPLING ERROR; SIMULATION; STATISTICS;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; RISK;

EID: 80055040711     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01222.x     Document Type: Review

References (19)

1. Peto R, Collins R, Gray R, (1995) Large-scale randomized evidence: large, simple trials and overviews of trials. Journal of Clinical Epidemiology, 48, 23-40.
2. Brookes S, Whitely E, Peters T, Mulheran PA, Egger M, Davey Smith G, (2001) Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5, 1-58.
3. Berlin JA, Begg CB, Louis TA, (1989) An assessment of publication bias using a sample of published clinical trials. Journal of the American Statistical Association, 84, 381-392.
4. Goodman SN, (2001) Of p-values and Bayes: a modest proposal. Epidemiology, 12, 295-297. (Pubitemid 32336390)
5. Poole C, (2001) Low p-values or narrow confidence intervals: which are more durable? Epidemiology, 12, 291-294. (Pubitemid 32336389)
6. Weinberg CR, (2001) It's time to rehabilitate the p-value. Epidemiology, 12, 288-290. (Pubitemid 32336388)
7. Rothwell PM, (2007) Reliable estimation and interpretation of the effects of treatment in subgroups. In:, Rothwell PM, ed. Treating individuals: from randomised trials to personalised medicine. Philadelphia: Elsevier, 169-182.
8. Land CE, (1980) Estimating cancer risks from low doses of ionizing radiation. Science, 209, 1197-1203. (Pubitemid 10019749)
9. Egger M, Smith GD, (1995) Misleading meta-analysis. British Medical Journal, 310, 752-754.
10. Egger M, Smith GD, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315, 629-634. (Pubitemid 27387172)
11. Hennekens CH, DeMets D, (2010) The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. Journal of the American Medical Association, 302, 2361-2362.
12. Hennekens CH, DeMets DL, Merz CNB, Borzak SL, Borer JS, (2010) Doing more good than harm: need for a cease fire. American Journal of Medicine, 122, 315-316.
13. Bresalier RS, Sandler RS, Quan H, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal andenoma chemoprevention trial. New England Journal of Medicine, 352, 1092-1102. (Pubitemid 40365350)
14. Food and Drug Administration Advisory Committee (2001) Cardiovascular safety review of rofecoxib. Technical report, Rockville, Maryland: Food and Drug Administration/Centre for Drug Evaluation and Research.
15. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C, (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? meta-analysis of randomised trials. British Medical Journal, 332, 1302-1308.
16. Weir MR, Sperling RS, Reicin A, Gertz BJ, (2003) Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. American Heart Journal, 146, 591-604. (Pubitemid 37281702)
17. Farkouh ME, Kirshner H, Harrington RA, et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 364, 675-684. (Pubitemid 39140623)
18. Lyseng-Williamson K, Curran M, (2004) Lumiracoxib. Drugs, 64, 2237-2246. (Pubitemid 39382213)
19. Waksman JC, Brody A, Phillips SD, (2007) Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe? The Annals of Pharmacotherapy, 41, 1163-1173. (Pubitemid 47122553)